Last Update 23 Mar 26

Fair value Increased 11%

TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup

Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables.

Analyst Commentary

Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.

Bullish Takeaways

Bullish analysts see solid early adoption of new products following recent industry conferences. They view this as supportive for execution on growth initiatives and future revenue contribution.
The single cell competitive setup is described as favorable by bullish analysts. They see this as helpful for defending share and supporting current valuation assumptions.
Higher price targets from several firms signal increased confidence that the company can monetize its platform across instruments and consumables over time, even with mixed end market trends.
Some analysts highlight double digit growth expectations in spatial consumables as a key offset to pressure in other consumable lines. They see this as supportive for the overall consumables franchise.

Bearish Takeaways

Bearish analysts point to muted academic demand expected in 2026, despite positive headlines around U.S. academic funding. They see this as a headwind for near term growth and a factor in more cautious rating stances.
A projected 10% decline in instrument revenue as customers wait for more consistent funding disbursements is flagged as a risk to execution and a factor that could weigh on how investors view the durability of the installed base.
In consumables, continued pressure in single cell products following 20% pricing declines tied to Flex Apex adoption is seen as a drag on margins and a key consideration for valuation.
Some research notes describe a higher bar for upcoming results after recent share rallies. Bearish analysts see this as increasing the risk that any shortfall on guidance or product uptake could trigger a reset in expectations.

What's in the News

Issued full year 2026 revenue guidance in a range of US$600 million to US$625 million, giving investors a concrete top line framework to track against management goals (Corporate guidance).
Partnered with PharosAI, which will use the Xenium spatial platform to turn archived NHS cancer samples into large scale, AI ready cancer datasets backed by PS18.9 million in UK government and partner funding (Key developments).
Announced a multi year collaboration with Dana Farber Cancer Institute using Chromium Flex and Xenium to study tumor samples from major solid cancers and to support potential future diagnostic workflows, alongside plans to build a CLIA certified lab (Key developments).
Expanded work in autoimmune disease through a Brigham & Women's Hospital collaboration using Chromium Flex to profile 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis, plus healthy controls, over time (Key developments).
Joined CareDx in the ImmuneScape program, supplying Xenium and Chromium Flex to generate high resolution maps of transplant organ rejection biology that may support future diagnostic development (Key developments).

Valuation Changes

Fair Value increased from $18.08 to $20.14, implying a modest rise in what analysts' updated model suggests as underlying worth per share.
The Discount Rate remained at 7.84%, so the required return used in the model is stable.
Revenue Growth moved higher from 2.95% to 3.36%, indicating a slightly stronger top line growth assumption in the latest update.
Net Profit Margin declined from 16.15% to 15.52%, reflecting a modestly lower profitability assumption in the new model.
Future P/E increased from 28.06x to 32.56x, pointing to a higher multiple being applied to expected earnings in the updated valuation work.

4 views

Key Takeaways

Expansion of product offerings and strategic acquisitions are enhancing innovation, reducing operational costs, and solidifying leadership in advanced genomics tools.
Growth in global partnerships and improved international presence are increasing market opportunities and supporting resilient, long-term revenue streams.
Macroeconomic pressures, shrinking pricing power, product shifts, and ongoing losses are undermining revenue growth, margin stability, and the path to profitability.

Catalysts

About 10x Genomics

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.
Recent and upcoming product launches-including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein-are expanding the range of applications and reinforcing 10x's leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.
The acquisition of Scale Biosciences broadens 10x Genomics' technical capabilities in single-cell analysis, allowing integration of foundational innovations like combinatorial indexing and quantum barcoding, which may accelerate innovation, reduce costs, and open up new high-value markets, positively impacting future revenue growth and margins.
Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements-which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.
Strengthening international distribution, particularly improved execution in China and Europe, together with strategic responses to tariff and CapEx headwinds, helps 10x diversify regional risks and access untapped markets, enhancing revenue growth resilience despite the currently challenging US academic funding environment.

10x Genomics Earnings and Revenue Growth

10x Genomics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming 10x Genomics's revenue will grow by 3.4% annually over the next 3 years.
Analysts are not forecasting that 10x Genomics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate 10x Genomics's profit margin will increase from -6.8% to the average US Life Sciences industry of 15.5% in 3 years.
If 10x Genomics's profit margin were to converge on the industry average, you could expect earnings to reach $110.2 million (and earnings per share of $0.77) by about March 2029, up from -$43.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 32.7x on those 2029 earnings, up from -54.0x today. This future PE is lower than the current PE for the US Life Sciences industry at 34.6x.
Analysts expect the number of shares outstanding to grow by 3.75% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.84%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing macroeconomic and funding uncertainty, especially in the US and Europe, is dampening academic and government research budgets, leading to conservative spending, extended project timelines, delays in equipment purchases, and heightened price sensitivity-directly pressuring future revenue growth and earning stability.
Lower average selling prices and continued discounting of instruments (notably Chromium and spatial platforms) to address customers' CapEx constraints indicate shrinking pricing power and may compress gross margins over time, especially as capital spending headwinds persist.
Product transitions to lower-cost solutions (e.g. GEM-X Flex, Flex v2, and Scale Biosciences' combinatorial indexing), while driving higher reaction volumes, are creating a near-term headwind to consumables revenue growth, as price declines are not yet fully offset by increased volume, risking overall revenue and operating leverage.
Temporary boosts in key geographies (such as APAC/China) from one-off events like tariff-related pull forwards may not be sustainable, while geopolitical risks and possible export restrictions could impact international expansion potential and geographically diversify revenue streams.
Persistent operating losses (excluding one-off gains from litigation settlements) and the need for ongoing cost discipline in R&D and SG&A suggest that, despite cash reserves, the business remains vulnerable to weaker top-line performance and delayed return to profitability-making net earnings recovery uncertain in a prolonged challenging environment.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $20.14 for 10x Genomics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $17.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $709.8 million, earnings will come to $110.2 million, and it would be trading on a PE ratio of 32.7x, assuming you use a discount rate of 7.8%.
Given the current share price of $18.39, the analyst price target of $20.14 is 8.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on 10x Genomics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Advanced Genomics Tools Will Shape Future Precision Medicine